2US Stock Overview A clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
NextCure, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NextCure Historical stock prices Current Share Price US$0.74 52 Week High US$2.28 52 Week Low US$0.74 Beta 0.61 1 Month Change -32.51% 3 Month Change -37.12% 1 Year Change -28.10% 3 Year Change -85.30% 5 Year Change -98.58% Change since IPO -95.77%
Recent News & Updates
Insufficient new directors Dec 30
NextCure, Inc. Announces Acceptance of IND Application for LNCB74 Dec 11
NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody Nov 20
New minor risk - Share price stability Nov 14
NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting Nov 06
Insufficient new directors Nov 01 See more updates
Insufficient new directors Dec 30
NextCure, Inc. Announces Acceptance of IND Application for LNCB74 Dec 11
NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody Nov 20
New minor risk - Share price stability Nov 14
NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting Nov 06
Insufficient new directors Nov 01
NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 May 31
New major risk - Revenue and earnings growth May 05
NextCure, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 Apr 10
NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board Apr 04
New major risk - Revenue and earnings growth Mar 25
New major risk - Share price stability Mar 23
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders Jan 20
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury Dec 22
Nextcure, Inc. Provides Year-End Clinical Pipeline Updates Dec 15
NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML Nov 17
New major risk - Revenue and earnings growth Nov 04
NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605 Oct 19
NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease Sep 27
NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors Jul 22
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting Nov 08
NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board Oct 28
NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors Oct 06
NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM Jun 28
Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board Jun 23
High number of new directors May 31
NextCure, Inc., Annual General Meeting, Jun 23, 2022 May 02
High number of new directors Apr 27
Now 23% undervalued after recent price drop Apr 20
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation Apr 20
NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting Dec 14
High number of new directors Nov 02
Independent Director Xiaoxing Xu has left the company Oct 07 NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index
Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410 Jun 22
Independent Director has left the company Apr 07
Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019) Mar 05
Revenue misses expectations Mar 05
NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021 Feb 26
The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc Jan 28
New 90-day high: €10.60 Jan 16
NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer Jan 15
NextCure, Inc. Provides Updates on NC318 Clinical Program Dec 19
Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action Nov 16
Revenue in line with expectations Nov 07
New 90-day high: €10.30 Oct 26
Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc Oct 14
Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws Oct 03
Nextcure, Inc. Announces Resignation of Kevin N. Heller from Chief Medical Officer Sep 24
Scott+Scott Attorneys At Law LLP Files Securities Class Action Against NextCure Inc Sep 22
New 90-day low - €7.35 Sep 01
First half earnings released Aug 07
New 90-day low - €7.70 Jul 30
NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Value Index Jul 03
NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Index Jul 02 NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Biotechnology Select Industry Index Jun 22
Shareholder Returns 2US DE Biotechs DE Market 7D -20.0% 2.3% 0.3% 1Y -28.1% -11.7% 8.4%
See full shareholder returns
Return vs Market: 2US underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is 2US's price volatile compared to industry and market? 2US volatility 2US Average Weekly Movement 9.8% Biotechs Industry Average Movement 7.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2US's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2US's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.
Show more NextCure, Inc. Fundamentals Summary How do NextCure's earnings and revenue compare to its market cap? 2US fundamental statistics Market cap €21.04m Earnings (TTM ) -€57.02m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2US income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$58.52m Earnings -US$58.52m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 04:02 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NextCure, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Aydin Huseynov Benchmark Company Alec Stranahan BofA Global Research null null BTIG
Show 7 more analysts 
